frontMIND Results: Tafasitamab-Based Combo Yields Significant PFS Benefit Over R-CHOP in Frontline High-Risk DLBCL

Tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) and R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone] generated a statistically significant improvement in progression-free survival (PFS) compared with R-CHOP alone in patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL), according to data from the phase 3 frontMIND trial (NCT04824092) presented during a press briefing ahead of the 2026 ASCO Annual Meeting.¹

Data displayed that at a median follow-up of 35.2 months, patients who received the tafasitamab-based regimen (n = 448) achieved a 2-year PFS rate of 71.1% compared with 62.9% with R-CHOP alone (n = 451). Moreover, patients in the tafasitamab arm experienced a 3-year PFS rate of 67.3% vs 60.7% in R-CHOP alone. Ultimately, tafasitamab plus lenalidomide and R-CHOP led to a 25% reduction in the risk of disease progression or death (HR, 0.75; 95% CI, 0.59-0.96; P = .0194).

Notably, the addition of tafasitamab and lenalidomide to R-CHOP did not impact the delivery of R-CHOP, with patients achieving a median relative dose intensity for R-CHOP of 100% in both arms throughout the duration of treatment.

“Everybody in the lymphoma community has been waiting for the first public disclosure of results from the frontMIND trial,” Paolo Strati, MD, told OncLive^® ahead of the meeting.¹ “frontMIND could be the third [positive] randomized, phase 3 study in the frontline setting for DLBCL…Later this year or early in 2027, we may be able to prescribe tafasitamab in the frontline setting [for DLBCL, if approved by the FDA].”

Strati is an associate professor in the Department of Translational Molecular Pathology of the Division of Cancer Medicine and an associate professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center in Houston, as well as an international faculty member in the Department of PhD program in Clinical and Experimental Oncology and Immunology at the University of Padova in Padua.

“This is the first of likely several entries into the frontline space for DLBCL. For the longest time, all we had was R-CHOP,” Tycel Phillips, MD, explained when discussing the significance of frontMIND. “Now, we could have 6 or 7 options, which is something that we would have thought was unheard of just a couple of years ago [for frontline DLBCL management].”

Phillips is an associate professor in the Department of Hematology and Hematopoietic Cell Transplantation in the Division of Lymphoma at City of Hope in Duarte, California.

How was frontMIND designed? What was the rationale behind evaluating tafasitamab plus lenalidomide and R-CHOP with R-CHOP alone?

Although R-CHOP has demonstrated curative potential in the frontline setting for patients with DLBCL, approximately 40% of patients, including those with high-risk disease, will experience progression.

The randomized, double-blind, global frontMIND study enrolled patients between 18 and 80 years of age with either previously untreated, high-rigk DLBCL or high-grade B-cell lymphoma. Patients also needed to have the following within 28 days of their diagnostic biopsy: an ECOG performance status of 2 or less, be candidates for R-CHOP, and have at least one measurable PET-positive lesion.

If patients had a history of prior non-hematologic malignancies (excluding malignancies treated with curative intent and no active disease for more 2 years before screening and adequately treated lentigo maligna or carcinoma), known central nervous system involvement, or contraindications to any R-CHOP individual components, they were not included in the trial.²

Patients in the tafasitamb arm recieved 12 mg/kg of intravenous (IV) tafasitamab on days 1, 8, and 15 of each cycle .¹ Daily 25 mg doses of lenalidomide on days 1 to 10 of each cycle and standard R-CHOP doses were also given to patients in the arm. The same doses and schedule were given to patients in the R-CHOP arm, except both tafasitamab and lenalidomide were placebo. Treatment cycles lasted 21 days and patients underwent 6 total treatment cycles.

PFS per investigator assessment was the primary end point of the trial, whereas event-free survival (EFS) and overall survival (OS) served as secondary end points. Other secondary end points were overall response rate (ORR) at end of treatment (EOT), PET-negative complete response (CR) rate at EOT, safety, and PFS by cell-of-origin subtypes.

Baseline characteristics among all patients in the trial (n = 899) revealed that patients had a median age of 65 years (range 18-80) and were mostly male (52.6%). Most patients also had stage III or IV Ann Arbor disease at the time of enrollment (96.6%) and elevated lactate dehydrogenase levels (82.9%). Less patients had extranodal involvement at 2 or more sites (38.7%), an ECOG performance status of 2 (31.5%), or were high-risk (43.2%). Bulky disease was present in most patients (53.9%) and patients had a median time from diagnostic biopsy to treatment initiation of 24 days (range, 18-28).

Cell-of-origin molecular subtypes for patients who underwent assessment (n = 484) were GCB-like (51.2%), ABC-like (35.5%), and unclassified (13.2%).

What were the additional data for tafasitamab plus lenalidomide and R-CHOP in high-risk DLBCL?

EFS rates at 2 and 3 years were also significantly improved by the tafasitamab-based regimen, demonstrating respective rates of 65% and 61.2% compared with 56.7% and 54.8%, respectively, with R-CHOP alone. A statistically significant improvement in EFS was observed (HR, 0.79; 95% CI, 0.64-0.97; P = . 0260).

Interim OS data also favored the tafasitamab arm (HR, 0.85; 95% CI, 0.63-1.14; P = 0.2703), with the final analysis set to be conducted at 5 years. The 2- and 3-year OS rates were 84.1% and 81.1%, respectively, in the tafasitamab arm vs 80.5% and 77.8%, respectively, for R-CHOP alone.

Two-year PFS rates for patients with centrally confirmed lymphoma subtypes (n =773) were 72.2% in the tafasitamab arm compared with 62.2% in the R-CHOP arm (HR, 0.68; 95% CI, 0.52-0.88; P = .0035).

In terms of responses, patients in the tafasitmab arm demonstrated an overall response rate of 80.4% (95% CI, 76.4-83.9) vs 76.1% (95% CI, 71.8-79.9) for R-CHOP alone (odds ratio [OR], 1.29; 95% CI, 0.94-1.78; P = .1201). Patients in both arms achieved a PET-negative CR rate of 65.2% (OR, 1; 95% CI, 0.76-1.31; P = .9873). Partial responses (PR), stable disease (SD), progressive disease (PD), and not evaluable (NE) responses occurred in 15.2%, 0.4%, 6.3%, and 12.9% of patients in the tafasitamab arm, respectively. Response rates for PR, SD, PD, and NE, broke down in the R-CHOP alone arm as 10.9%, 1.1%, 11.1%, and 11.8%, respectively.

Regarding safety, the tafasitamab regimen had a similar safety profile of R-CHOP alone, with any-grade treatment-emergent adverse effects (TEAEs) occurring in 98.6% and 91.7% of patients in the respective arms. Rates of grade 3 or higher TEAEs were higher with the in the experimental arm (86.7%) compared with R-CHOP alone (76.1%). Serious TEAEs in occured at rates of 50.1% and 38.9% of each of the respective arms, in addition to fatal TEAEs occurring at rates of 5.9% and 5.4%. Similar rates of treatment discontinuation occurred in each arm, with 15.8% of patients discontinuing treatment in the tafasitamab arm and 14.6% doing so in the R-CHOP alone arm.

Rates of treatment discontinuation due to TEAEs were similar between the tafasitamab arm (5.2%) and the R-CHOP alone arm (5.4%), with less deaths occurring in the tafasitamab arm (18.5%) than R-CHOP alone (21.7%).

Common TEAEs that occurred in at least 12% of patients in each arm were neutropenia (tafasitamab, 70.7%; R-CHOP alone, 59.7%), anemia (46.3%; 34.5%), peripheral neuropathy (40.6%; 39.1%), thrombocytopenia (38.8%; 26.6%), constipation (34.3%: 28.2%), and nausea (26.4%; 31.3%).

“There might be some patients that you might be favoring R-CHOP that you [will now] instead favor R-CHOP plus tafasitamab and lenalidomide. [The frontMIND regimen] could represent a new first-line treatment option for selected patients,” Brad Kahl, MD, added about the impact of the regimen in clinical practice.

Kahl is a professor of medicine in the Division of Oncology and director of the Lymphoma Program at Washington University School of Medicine in St. Louis, Missouri.

References

1. Lenz G, Trněný M, Burke JM, et al. frontMIND: Phase 3 study of tafasitamab plus lenalidomide and R-Chop for patients with newly diagnosed diffuse large B-cell lymphoma. J Clin Oncol. 2026;44(suppl 17):LBA7000. 10.1200/JCO.2026.44.17_suppl.LBA7000
2. Tafasitamab + lenalidomide + R-CHOP versus R-CHOP in newly diagnosed high-intermediate and high risk DLBCL patients (frontMIND). ClinicalTrials.gov. Updated April 1, 2026. Accessed May 29, 2026. https://clinicaltrials.gov/study/NCT04824092